Get the Stockscreener App
2.21
4.25%
0.09
Pre-market:
2.22
0.01
+0.45%
Eledon Pharmaceuticals Inc stock is traded at $2.21, with a volume of 828.46K.
It is up +4.25% in the last 24 hours and up +34.76% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$2.12
Open:
$2.09
24h Volume:
828.46K
Relative Volume:
0.40
Market Cap:
$165.83M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.2346
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+12.18%
1M Performance:
+34.76%
6M Performance:
-40.27%
1Y Performance:
-45.02%
1-Day Range:
$2.09
$2.25
1-Week Range:
$1.905
$2.25
52-Week Range:
$1.35
$4.965
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.21 | 159.07M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.08 | 111.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.78 | 77.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
809.64 | 49.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.53 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.28 | 37.42B | 4.98B | 69.59M | 525.67M | 0.5197 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Surprises Report: Is SDHC stock a value trapEarnings Overview Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Loss Report: Is Eledon Pharmaceuticals Inc stock a good dividend stock2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Growth Value: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts - Defense World
Buy Signal: Will Eledon Pharmaceuticals Inc stock deliver better than expected guidanceJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - Bộ Nội Vụ
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Eledon Pharmaceuticals Shares Sink After Announcing $50 Million Public Offering - MSN
Profit Review: Can Eledon Pharmaceuticals Inc. stock sustain market leadershipQuarterly Portfolio Report & Stepwise Swing Trade Plans - ulpravda.ru
Can Eledon Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - Улправда
How Eledon Pharmaceuticals Inc. (2TK) stock trades after earningsQuarterly Earnings Report & Community Verified Trade Signals - ulpravda.ru
Eledon’s tegoprubart shows promise in kidney transplantation trials By Investing.com - Investing.com South Africa
Eledon’s tegoprubart shows promise in kidney transplantation trials - Investing.com
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - The Manila Times
Can Eledon Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Update & Verified Entry Point Signals - Улправда
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3%Time to Buy? - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3% – Time to Buy? - Defense World
Is Eledon Pharmaceuticals Inc. (2TK) stock a defensive play amid uncertaintyCandlestick Pattern Analysis & Free Expert Stock Watchlists - ulpravda.ru
Cash per share of Eledon Pharmaceuticals, Inc. – MUN:2TK - TradingView — Track All Markets
Midday Stock Roundup: Lantronix Stock up 4.8% Today - Orange County Business Journal
Eledon Pharmaceuticals Restructures Stake via Pre-Funded Warrant - TipRanks
Midday Stock Roundup: Rivian Down on Production Totals - Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Eledon Pharmaceuticals (STU:2TK) EV-to-OCF : -0.29 (As of Dec. 31, 2025) - GuruFocus
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - Morningstar
Is Eledon Pharmaceuticals Inc. (2TK) stock a buy during volatile marketsProtective Put Strategies & Small Capital Growth Tips - bollywoodhelpline.com
Midday Stock Roundup: Shimmick Corp. climbs 14% - Orange County Business Journal
Sector Rotation Brings Aditya Birla Sun Life Amc Ltd Into FocusSmall Cap Stock Opportunities & Free ETF and Mutual Fund Comparisons - earlytimes.in
Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today? - MSN
Can Eledon Pharmaceuticals Inc. stock double in next 5 yearsStochastic Oscillator Alerts & Free High Yield Growth Strategies - Bollywood Helpline
Eledon Pharmaceuticals Inc (ELDN) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Analysts Set Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Target Price at $9.67 - Defense World
Midday Stock Roundup: Rivian Stock Continues to Climb - Orange County Business Journal
Eledon Pharmaceuticals Earnings Notes - Trefis
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Midday Stock Roundup: Rivian Rises on Chip, Models - Orange County Business Journal
Eledon prices $50 million public offering of stock and warrants By Investing.com - Investing.com Nigeria
Net current asset value per share of Eledon Pharmaceuticals, Inc. – DUS:2TK - TradingView — Track All Markets
Kidney Transplant Rejection Market on Track for Major Expansion by 2034, According to DelveInsight | GE Healthcare, Viela Bio, Eledon Pharma, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor - Barchart.com
Kidney Transplant Rejection Market on Track for Major Expansion - openPR.com
Eledon Pharmaceuticals Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Free Stock Index Interpretations - earlytimes.in
Why Eledon Pharmaceuticals Inc. stock is favored by pension fundsQuarterly Portfolio Review & Daily Profit Focused Screening - Newser
How analysts revise price targets for Eledon Pharmaceuticals Inc. (2TK) stockRisk Management & High Conviction Trade Alerts - Newser
Published on: 2025-12-04 05:40:36 - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Is Eledon Pharmaceuticals Inc. (2TK) stock attractive post correctionBond Market & Verified High Yield Trade Plans - Newser
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.85%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):